135 related articles for article (PubMed ID: 37898545)
1. CD39 deletion in TCR-engineered T cells enhances antitumour immunity.
Tsai AK; Stromnes IM
Gut; 2024 Apr; 73(5):716-717. PubMed ID: 37898545
[No Abstract] [Full Text] [Related]
2. The CD39
Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
4. Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
Potenza A; Balestrieri C; Spiga M; Albarello L; Pedica F; Manfredi F; Cianciotti BC; De Lalla C; Botrugno OA; Faccani C; Stasi L; Tassi E; Bonfiglio S; Scotti GM; Redegalli M; Biancolini D; Camisa B; Tiziano E; Sirini C; Casucci M; Iozzi C; Abbati D; Simeoni F; Lazarevic D; Elmore U; Fiorentini G; Di Lullo G; Casorati G; Doglioni C; Tonon G; Dellabona P; Rosati R; Aldrighetti L; Ruggiero E; Bonini C
Gut; 2023 Oct; 72(10):1887-1903. PubMed ID: 37399271
[TBL] [Abstract][Full Text] [Related]
5. CD39 Regulation and Functions in T Cells.
Timperi E; Barnaba V
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360833
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
7. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
[TBL] [Abstract][Full Text] [Related]
8. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes.
Raczkowski F; Rissiek A; Ricklefs I; Heiss K; Schumacher V; Wundenberg K; Haag F; Koch-Nolte F; Tolosa E; Mittrücker HW
PLoS One; 2018; 13(5):e0197151. PubMed ID: 29742141
[TBL] [Abstract][Full Text] [Related]
9. CD39
Tallón de Lara P; Castañón H; Vermeer M; Núñez N; Silina K; Sobottka B; Urdinez J; Cecconi V; Yagita H; Movahedian Attar F; Hiltbrunner S; Glarner I; Moch H; Tugues S; Becher B; van den Broek M
Nat Commun; 2021 Feb; 12(1):769. PubMed ID: 33536445
[TBL] [Abstract][Full Text] [Related]
10. CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells.
Boer MC; van Meijgaarden KE; Bastid J; Ottenhoff TH; Joosten SA
Eur J Immunol; 2013 Jul; 43(7):1925-32. PubMed ID: 23606272
[TBL] [Abstract][Full Text] [Related]
11. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
12. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
[TBL] [Abstract][Full Text] [Related]
13. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
[TBL] [Abstract][Full Text] [Related]
14. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
Nagate Y; Ezoe S; Fujita J; Okuzaki D; Motooka D; Ishibashi T; Ichii M; Tanimura A; Kurashige M; Morii E; Fukushima T; Suehiro Y; Yokota T; Shibayama H; Oritani K; Kanakura Y
Leukemia; 2021 Jan; 35(1):107-118. PubMed ID: 32203145
[TBL] [Abstract][Full Text] [Related]
15. CD39 identifies a microenvironment-specific anti-inflammatory CD8
van Duijn J; van Elsas M; Benne N; Depuydt M; Wezel A; Smeets H; Bot I; Jiskoot W; Kuiper J; Slütter B
Atherosclerosis; 2019 Jun; 285():71-78. PubMed ID: 31048101
[TBL] [Abstract][Full Text] [Related]
16. CD39+ regulatory T cells attenuate allergic airway inflammation.
Li P; Gao Y; Cao J; Wang W; Chen Y; Zhang G; Robson SC; Wu Y; Yang J
Clin Exp Allergy; 2015 Jun; 45(6):1126-37. PubMed ID: 25728362
[TBL] [Abstract][Full Text] [Related]
17. CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39.
Zhang X; Ouyang X; Xu Z; Chen J; Huang Q; Liu Y; Xu T; Wang J; Olsen N; Xu A; Zheng SG
Mol Ther; 2019 Nov; 27(11):1963-1973. PubMed ID: 31402273
[TBL] [Abstract][Full Text] [Related]
18. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
Sun X; Wu Y; Gao W; Enjyoji K; Csizmadia E; Müller CE; Murakami T; Robson SC
Gastroenterology; 2010 Sep; 139(3):1030-40. PubMed ID: 20546740
[TBL] [Abstract][Full Text] [Related]
19. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
[TBL] [Abstract][Full Text] [Related]
20. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
